Continuing our discussion about Medicare Drug Price Negotiations.
Amgen’s Enbrel, Bristol Myers Squibb’s Eliquis and Johnson & Johnson’s Stelara will account for 51.4% of the Inflation Reduction Act’s drug price negotiation savings in 2026, according to the Brookings Institution.
A little known feature of the IRA gave CMS the ability to negotiate drug prices.
These savings indicate how much of the federal government's budget goes to Medicare's drug benefit for seniors.
The drugs were designed to treat some of the most frequent illnesses in the population, arthritis, blood clots in heart disease, and psoriasis.
No comments:
Post a Comment